Adipotide vs AOD-9604
A targeted fat-destroying peptide that works like a smart missile, cutting off blood supply to fat cells and causing rapid weight loss in primate studies.
A modified fragment of human growth hormone that targets fat cells for breakdown without affecting blood sugar or muscle growth—your metabolism's precision tool.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Adipotide
mg/kg
AOD-9604
300–400 mcg
Frequency
Adipotide
Once daily
AOD-9604
Once daily
Administration
Adipotide
Subcutaneous injection
AOD-9604
Subcutaneous injection
Cycle length
Adipotide
4-6 weeks
AOD-9604
8-12 weeks
Onset speed
Adipotide
Moderate (1-2 weeks)
AOD-9604
Gradual (3-4 weeks)
Evidence level
Adipotide
Strong preclinical (extensive animal studies)
AOD-9604
Moderate human trials (Phase 1-2)
Benefit ratings
Fat Elimination
Metabolic Improvement
Speed of Results
Fat Targeting
Safety Profile
Joint Support
Compound specifications
Adipotide
Molecular formula
C111H206N36O28S2
Molecular weight
2611.41 g/mol
Half-life
~24 hours
Bioavailability
High (subcutaneous injection)
CAS number
859216-15-2
AOD-9604
Molecular formula
C78H123N23O23S2
Molecular weight
1815.1 g/mol
Half-life
~3-4 minutes (plasma)
Bioavailability
High (subcutaneous)
CAS number
221231-10-3
Dosing compared
Adipotide
Subcutaneous
0.10 mg/kg
Once daily · About 2 weeks before stepping up
Adipotide is research-only and has never been approved for people. These numbers come from a dose-finding study in obese monkeys, where the dose was raised step by step every 2 weeks [2]. The first-in-man Phase 1 study started lower, at 0.03 mg/kg under the skin once daily for 28 days; it enrolled 4 people and was terminated without posting results [5].
0.25 mg/kg
Once daily · About 2 weeks at this step
Middle step in the rhesus macaque dose-finding study — not an approved or established human dose. Renal tubular degeneration with elevated creatinine was dose-dependent in those macaques, and this level sits at the point where that injury was observed. The mechanism makes it expected rather than incidental: adipotide is a homing sequence fused to a pro-apoptotic domain, and the kidney accumulates it. [2]
0.43 mg/kg
Once daily · Up to ~3-4 weeks at this level (studies ran 28 days at the top dose)
This was the best-working ("optimal") dose in obese monkeys, leading to about 10.6% body-weight loss over 28 days. It is from animal research and is not an approved or established human dose. [2]
AOD-9604
Subcutaneous
250 mcg
Once daily · 2-4 weeks
AOD9604 is a research peptide and not an approved medicine. Doses around 250 mcg under the skin are a common starting point in practice. In a human trial the most effective amount was about 1 mg per day. [1][5]
300-400 mcg
Once daily · 8-12 weeks
A commonly used daily amount in practice. The largest human study found benefit up to about 1 mg/day with no extra gain from higher doses. [1][5]
500 mcg
Once daily · 8-12 weeks
A higher amount sometimes used in practice. Going above roughly 1 mg/day did not improve results in the human trial. [1][5]
Best suited for
Adipotide
Targeted White Fat Reduction
Adipotide specifically seeks out and destroys the blood vessels feeding white adipose tissue. Unlike diet or exercise that shrink fat cells, this peptide actually eliminates fat tissue by cutting off its blood supply - a completely unique mechanism.
Stubborn Fat Deposits
Because it targets the vasculature of fat tissue directly, Adipotide may be particularly effective for stubborn fat deposits that resist traditional methods. The peptide homes in on prohibitin receptors found specifically on blood vessels supplying fat tissue.
Improving Insulin Resistance
Primate studies showed remarkable improvements in insulin sensitivity - treated monkeys used about 50% less insulin after treatment. This makes it interesting for research into obesity-related metabolic dysfunction.
Research Applications
As a pioneering vascular-targeting peptide, Adipotide represents a new class of potential therapeutics. Its unique mechanism of targeting specific tissue vasculature has implications beyond obesity research.
AOD-9604
Targeted Fat Loss
AOD-9604 shines when you want to target stubborn fat deposits. It works by mimicking how growth hormone breaks down fat, but without the side effects of actual HGH. Think of it as a smart missile that targets fat cells specifically.
Body Recomposition
Perfect for those who want to lose fat while maintaining muscle. Unlike many fat loss compounds, AOD-9604 doesn't affect muscle tissue or mess with your blood sugar levels—it's laser-focused on fat metabolism.
Metabolic Enhancement
Ideal for boosting your metabolism naturally. AOD-9604 increases fat oxidation (your body's ability to burn fat for fuel) without the jittery stimulant effects of caffeine or other thermogenics.
Joint Health Support
Emerging research shows AOD-9604 may help repair cartilage and support joint health. Studies in osteoarthritis models show it can reduce cartilage damage, making it a dual-purpose peptide for active individuals.
Metabolically Safe Fat Loss
Unlike many weight loss compounds, AOD-9604 doesn't raise blood sugar, doesn't affect insulin, and doesn't stimulate cell growth. It's one of the gentlest approaches to enhancing fat metabolism available.
Side effects
Adipotide
Common
- Elevated Serum Creatinine
- Proteinuria
- Glucosuria
- Reduced Appetite
Uncommon
- Mild Dehydration
- Injection Site Reactions
Serious
- Renal Tubular Dysfunction
AOD-9604
Common
- Injection site reactions
- Mild headache
- Flushing or warmth
Uncommon
- Fatigue
- Dizziness
Serious
- Allergic reaction
Safety & evidence
Adipotide
Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
Everything known about adipotide's safety comes from animals. It has been given to mice [1], to mice and rats [4], and to obese monkeys of three different species [2]. The main safety finding is the kidneys. In the monkey study, the doses that worked best also produced changes in the function of the renal proximal tubule — the part of the kidney that reabsorbs what the body needs from filtered blood. Those changes were dose-dependent and they reversed after treatment stopped [2]. The selectivity claim comes from a direct comparison rather than an impression: the same peptide that completely reversed diet-induced obesity in mice on a high-fat diet did not reduce body weight in animals on a low-fat diet [4]. There is no human safety data. One first-in-man Phase 1 study opened in 2012 in men with metastatic prostate cancer and obesity. Four people were enrolled. It was terminated, the registry records the reason as the principal investigator's request rather than a safety finding, and no results have ever been posted [5].
Contraindications
- Kidney disease or impaired renal function
- Pregnancy or breastfeeding
- Active infections or compromised immune system
- History of severe allergic reactions to peptides
- Dehydration or conditions affecting fluid balance
AOD-9604
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not FDA approved
Safety overview
AOD-9604 has been studied in multiple human clinical trials involving thousands of participants. The safety profile is notably clean—it doesn't affect blood sugar, insulin levels, or cause the typical side effects of growth hormone. Phase 2 trials showed it was well-tolerated even at doses higher than typically used. The most common side effects are mild and injection-site related.
Contraindications
- Pregnancy or breastfeeding
- Active cancer or history of cancer
- Known allergy to growth hormone-derived peptides
- Children and adolescents
Which is right for you?
Choose Adipotide if...
- Targeted fat reduction
- Improving insulin resistance
- Reducing stubborn white adipose tissue
- Research into vascular-targeted therapies
Choose AOD-9604 if...
- Fat loss
- Body composition improvement
- Metabolic support
- Joint health support